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Abstract
We present a generic dendritic cell (DC) vaccine strategy for patients with renal cell carcinoma
(RCC) based on the use of RNA as a source of multiplex tumor-associated antigens (TAAs). Instead
of preparing RNA from tumor tissue of each individual RCC patient, we propose to substitute RNA
prepared from a well characterized highly immunogenic RCC cell line (RCC-26 tumor cells) as a
generic source of TAAs for loading of DCs. We demonstrate here that efficient RNA transfer can
be achieved using lipofection of immature DCs, which are subsequently matured with a cytokine
cocktail to express high levels of MHC and costimulatory molecules as well as the chemokine
receptor CCR7. Neither RNA itself nor the lipid component impacted on the phenotype or the
cytokine secretion of mature DCs.
Following RNA loading, DCs derived from HLA-A2-positive donors were able to activate effector-
memory cytotoxic T lymphocytes (CTLs) specific for a TAA ligand expressed by the RCC-26 cell
line. CTL responses to RNA-loaded DCs reached levels comparable to those stimulated directly
by the RCC-26 tumor cells. Furthermore, DCs expressing tumor cell RNA primed naïve T cells,
yielding T cell lines with cytotoxicity and cytokine secretion after contact with RCC tumor cells.
RCC-26 cell lines are available as good manufacturing practice (GMP)-certified reagents enabling
this source of RNA to be easily standardized and adapted for clinical testing. In addition, well
defined immune monitoring tools, including the use of RNA expressing B cell lines, are available.
Thus, this DC vaccine strategy can be directly compared with an ongoing gene therapy trial using
genetically-engineered variants of the RCC-26 cell line as vaccines for RCC patients with metastatic
disease.
Background
Renal cell carcinomas (RCC) are classified as immuno-
genic tumors based on the observation that patients with
metastatic RCC show some of the most favorable
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responses to immunotherapy [reviewed in [1,2]]; tumor-
infiltrating lymphocytes (TIL) have been isolated that kill
autologous tumor cells following restimulation in vitro
[reviewed in [3]] and adoptive transfer of TIL provided
clinical benefit to some RCC patients [4-7]. It would be
desirable to exploit these reservoirs of effector cells in RCC
patients in order to improve antitumor immunity. This
could be achieved either by vaccinating patients to boost
pre-existing cellular immunity or by using adoptive trans-
fer of specific effector cells that have been activated and
expanded ex vivo.
Applying specific antigens for these purposes has been
hindered in RCC by a paucity of information regarding
the identity of tumor-associated antigens (TAAs) that can
serve as effective tumor rejection antigens. For example,
members of the cancer-germline family, like NY-ESO-1
molecules and several members of the MAGE family
which display suitable characteristics as immunogens for
other tumors, are not expressed in the majority of RCC [8-
12]. Therefore, vaccine developments for RCC have con-
centrated to date on the use of tumor cells themselves to
provide mixtures of unknown TAAs as immunogens. On
this basis, several types of autologous RCC vaccination
strategies have been evaluated in clinical trials, including
the use of inactivated tumor cells, gene-modified tumor
cells or DCs expressing antigens derived from RCC lysates,
tumor-RNA or following fusion with autologous tumor
cells [reviewed in [13]]. While these approaches were
found to be feasible, demonstrated limited toxicity, and
showed some bioactivity and clinical impact, long-term
vaccination was hindered by the lack of adequate
amounts of tumor from many patients. To overcome this
limitation, alternative strategies using allogeneic tumor
cell lines can be employed, whereby development of effec-
tive antitumor immunity relies on the presence of target
molecules that are shared among various RCC. CTL recog-
nition studies and molecular profiling of tumor cells sup-
port the validity of this contention for RCC [14-22].
We developed an allogeneic tumor cell vaccine using a
well characterized tumor line (RCC-26) that was derived
from a patient with early stage disease (T1, N0, M0). Stud-
ies of autologous and allogeneic TIL demonstrated that
this RCC line displayed a number of distinct peptide-
major histocompatibility complex (pMHC) ligands, some
of which were restricted by HLA-A*0201-encoded mole-
cules and shared by other RCCs. Autologous TIL-26 cells
recognized their specific pMHC ligands on RCC-26 cells
but not on cells derived from normal kidney parenchyma
(NKC-26) or Epstein- Barr virus-transformed lymphoblas-
toid cells (LCL-26) [14], revealing their tumor-associated
specificity. We genetically engineered RCC-26 cells to
express CD80 together with selected cytokines in order to
enhance their natural immunogenicity and we have initi-
ated a two-center trial comparing vaccine variants express-
ing CD80 with IL-2 or IL-7 in HLA-A*0201-matched
patients with metastatic disease [13,23].
While this allogeneic approach has the advantage that vac-
cines can be derived from well charcterized tumor cells
and a generic source of vaccine can be used in multiple
patients, it is limited by the fact that immunization may
only be optimally effective in patients who are partially
matched for HLA allotypes with the vaccine cells, since
encounter with DCs allowing cross-presentation of TAAs
may not be very efficient in vivo. Furthermore, if the vac-
cine cell is the direct APC for T cell stimulation, responses
are limited to CD8+ T cells because the RCC cells do not
express MHC class II molecules.
To overcome this limitation and allow patients with vari-
ous HLA allotypes to be entered into clinical trials, the
development of a vaccine using autologous DCs loaded
with tumor-derived RNA represents a promising new
approach [24]. We reasoned that RNA derived from our
well characterized RCC-26 cell line could be used not only
as a source of multiplex TAAs, but also could serve as a
tool for post-vaccination immune monitoring. Here we
report our strategy for the development of a generic RNA-
pulsed DC vaccine and the characterization of DCs loaded
with RCC-derived RNA.
Methods
Cell lines and cultures
The renal cell carcinoma cell line RCC-26 was established
from a primary stage I (T1, N0, M0, G2) clear cell carci-
noma of patient-26, as described previously [14] (HLA
alleles: A*0201, A*3303, B*4101, B*5101, Cw*1502 and
Cw*1701). The RCC- 53 cell line was generated similarly
from a second patient (T2, N1, M1, G2-3) with clear cell
carcinoma (HLA alleles: A*0201, A*2501, B*1501,
B*1801, Cw*1203 and Cw*0303) [25]. Epstein-Barr virus
(EBV)-transformed lymphoblastoid cell lines (LCLs) were
generated as described [26]. All cell lines were cultured in
RPMI 1640 medium supplemented with 12% fetal bovine
serum (FBS), 2 mM L-glutamine, 1 mM sodium pyruvate
and 1× non-essential amino acids. The TIL-26 cell line was
obtained from the primary tumor of patient-26 as pub-
lished [14], cultured in RPMI 1640 medium containing
7.5% FBS, 7.5% heat-inactivated, pooled human serum, 2
mM L-glutamine, 1 mM sodium-pyruvate and 1× non-
essential amino acids and restimulated every 14 days with
irradiated autologous tumor cells.
Generation of monocyte-derived DCs from peripheral 
blood mononuclear cells
Peripheral blood mononuclear cells (PBMCs) were iso-
lated by standard Ficoll-Paque (PAN Biotech, Aidenbach,
Germany) density gradient centrifugation of heparinizedJournal of Translational Medicine 2005, 3:29 http://www.translational-medicine.com/content/3/1/29
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blood obtained from healthy donors and washed twice in
PBS. Subsequently, CD14+ cells were affinity purified uti-
lizing the magnetic cell sorting kit (MACS) (Miltenyi Bio-
tec, Bergisch Gladbach, Germany), according to the
manufacturer's instructions. In brief, the isolated PBMCs
were incubated with CD14 MicroBeads in a concentration
of 15 µl/107 PBMCs in PBS containing 1% FBS at 4°C for
15 min. The labelled cells were washed once, passed
through a positive selection column, washed three times
and eluted from the column. To generate DCs, the CD14+
cells were cultured in X-Vivo 15 medium (Cambrex Bio
Science, Verviers, Belgium) supplemented with 800 U/ml
rhuGM-CSF (Leukine, Berlex, Richmond, USA) and 10
ng/ml rhuIL-4 (Promocell Bioscience, Heidelberg, Ger-
many) at a cell concentration of 1.5 × 106/ml in 6-well
culture plates (TPP, Peske, Aindling, Germany). For matu-
ration of immature DCs (iDCs), the cells were incubated
on day 6–7 with a cytokine cocktail containing 250 U/ml
rhuTNF-α, 20 ng/ml rhuIL-1β (Promocell Bioscience), 1
µM PGE2 (Sigma, Taufkirchen, Germany) and 1000 U/ml
rhuIL-6 (R&D Systems, Minneapolis, USA) for 48 h [27].
Additionally, the cultures were supplemented with 800 U/
ml rhuGM-CSF and 10 ng/ml rhuIL-4.
Isolation of total tumor RNA
Total tumor RNA was extracted from the human RCC cell
lines, RCC-26 and RCC- 53, using Tri Reagent® (Sigma)
according to the manufacturer's instructions.
Generation of in vitro-transcribed mRNA
In vitro-transcribed enhanced green fluorescent protein
(EGFP) mRNA was prepared using the vector pGEM4Z/
GFP/A64 [28] (kindly provided by E. Gilboa, The Center
for Cellular and Genetic Therapies, Duke University Med-
ical Center, Durham, NC, USA), which already contained
the poly(A) template. In vitro transcription under the con-
trol of a T7 promoter was carried out using the mMES-
SAGE mMACHINE™ T7 kit (Ambion, Austin, Texas, USA).
IVT mRNA was then purified using the RNeasy Mini Kit
(Qiagen, Hilden, Germany) following the RNA cleanup
protocol.
Transfection of DCs
Transfection of DCs with RNA was carried out using the
cationic lipid reagent DMRIE-C (Invitrogen, Karlsruhe,
Germany). On day 7, iDCs were harvested and resus-
pended in OptiMEM®I (Invitrogen) at a final concentra-
tion of 1.0 × 106  DCs/ml. This cell suspension was
distributed immediately in 24-well plates (0.5 ml/well =
0.5 × 106 iDCs/well). The RNA/lipid solution was pre-
pared as follows: for each DC culture well 0.5 ml Opti-
MEM®I was mixed with 5 µl DMRIE-C in a polystyrene
tube and the desired amount of RNA was subsequently
added to the mixture. In general, 2.5 – 5.0 µg of IVT
mRNA or 5.0 µg of total tumor RNA were applied for
transfection of 0.5 × 106 iDCs. The RNA/lipid solution
was transferred immediately to the iDCs. After a 4 h incu-
bation period at 37°C, the transfection solution was
removed and replaced by X-VIVO 15, supplemented with
the cytokine cocktail for DC maturation as indicated.
Flow cytometric analysis
Phenotypic analysis of DCs was carried out by immun-
ofluorescence staining of dendritic-monocyte differentia-
tion and activation markers. Cells were labelled with
mouse monoclonal antibodies (mabs) either unconju-
gated or directly conjugated with fluorescein isothiocy-
anate (FITC) or phycoerythrin (PE). The following FITC-
conjugated mabs were used: anti-HLA-DR (IgG2a, clone
G46-6), anti-CD83 (IgG1, clone HB15e), anti-DC-SIGN
(IgG2b, clone DCN46), anti-CD14 (IgG2a, clone M5E2)
(BD Pharmingen, San Diego, USA). The following mabs
were used as PE-conjugated reagents: anti-CD86 (IgG1,
clone 2331 FUN-1), anti-CD80 (IgG1, clone L307.4) (BD
Pharmingen), anti-CD40 (IgG1, clone mAb89) (Beckman
Coulter, Krefeld, Germany). Clone 2H4 specific for
human CCR7 (BD Pharmingen) was unconjugated. Indi-
rect immunofluorescence was performed using mono-
clonal biotin-conjugated rat-anti-mouse IgM (clone II/41)
in combination with PE-conjugated streptavidin (BD
Pharmingen). PE/FITC isotype-matched mouse immu-
noglobulins were used as negative controls (BD
Pharmingen).
Cells were washed once with PBS containing 1% FBS and
incubated with the appropriate mab for 30 min on ice in
PBS/1% FBS. Then cells were washed once again and fixed
in PBS/1% paraformaldehyde. Samples were acquired
using a FACSCalibur instrument (BD Bioscience Immu-
nocytometry Systems, San Jose, USA) and data analysis
was performed using CellQuest Pro software. For determi-
nation of EGFP expression, DCs were harvested approxi-
mately 24 h after transfection, washed once and directly
analyzed by flow cytometry.
Analysis of cytokine expression
Release of cytokines by DCs was measured using the
highly sensitive Bio-Plex human cytokine reagent kit (Bio-
Rad Laboratories Inc., Hercules, CA, USA), according to
the manufacturer's protocol. Data analysis was performed
using the BioRad Array Operation System (BioRad) and
applied five parameter logistic regression algorithms.
T cell stimulation assay
Stimulating cells were harvested and plated in triplicates
in 96-well U-bottomed plates at a concentration of 1.5 ×
104 cells per well in 100 µl of the appropriate T cell media.
T cells were added in a concentration of 3000 cells/well
(in the case of the TIL-26(GG) clone) or 1.5 × 104 cells/
well (in the case of de novo primed T cell lines) in 100 µl,Journal of Translational Medicine 2005, 3:29 http://www.translational-medicine.com/content/3/1/29
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yielding a total volume of 200 µl/well. Culture superna-
tants were harvested after a 24 h incubation period at
37°C and release of interferon-gamma (IFNγ) was meas-
ured using a commercially available enzyme-linked
immunosorbent assay (BD Pharmingen).
T cell priming
The generation of antitumor T cell lines was carried out
using autologous cells derived from blood of healthy vol-
unteers. Monocyte-derived iDCs were transfected with
total tumor RNA, as described above and matured for 48
h. In 24-well plates, 1.25 × 105 mDCs were incubated with
1 × 106 autologous PBMCs in a total volume of 2 ml/well
in RPMI 1640 medium containing 12% heat inactivated,
pooled human serum, 2 mM L-glutamine, 1 mM sodium-
pyruvate and 1× non-essential amino acids. After 10–12
days of culture, cells were restimulated with autologous
mDCs transfected with total cellular RNA in a ratio of 4:1
(PBMC:mDC). Subsequent rounds of restimulation were
carried out in an analogous manner, replacing stimulator
DCs every 7 days. 10 ng/ml rhuIL-7 (Promocell Bio-
science) and 20 U/ml rhuIL-2 (Proleukine®, Chiron,
Emeryville, CA, USA) were added to the culture three
times per week starting at days 12 and 18, respectively.
The cytolytic activity of induced CTLs was analyzed on day
4 after the last round of restimulation in a standard
51chromium-release assay. Release of IFNγ following T cell
stimulation was measured on day 10 after the last round
of restimulation, using a commercially available enzyme-
linked immunosorbent assay (BD Pharmingen).
51Chromium-release assay
Cell-mediated lysis was measured in a standard 51Cr-
release assay as described earlier [29]. In brief, target cells
were labelled with Na2
51CrO4 (Hartmann Analytic,
Braunschweig, Germany) at 37°C for 1 h and co-cultured
with the effector cells at the indicated effector:target (E:T)
cell ratios in a 96-well V-bottomed plate for 4 h. Sponta-
neous 51Cr-release was obtained by incubating target cells
alone and maximum release by directly counting labelled
cells only. The percentage of specific lysis was calculated
as: 100 × (experimental counts per minute (cpm) - spon-
taneous cpm) / (maximal cpm - spontaneous cpm). Trip-
licate measurements of four-step titrations of effector cells
were used for the experiments.
Results
Strategy for a generic RNA-pulsed DC vaccine for RCC 
patients
We foresee the following strategy for the development and
application of a generic RNA-pulsed DC vaccine for RCC
(Figure 1). In a first step, PBMCs from a metastatic RCC
(mRCC) patient are isolated before treatment to acquire
monocytes (Step 1a) and to generate autologous EBV-
transformed LCLs for long-term studies (Step 1b). In a sec-
ond step, the isolated monocytes are differentiated into
immature dendritic cells (iDCs) in the presence of GM-
CSF and IL-4 (Step 2). On day 7 of culture, iDCs are trans-
fected with total RNA derived from the RCC-26 cell line
and subsequently matured using a defined pro-inflamma-
tory cytokine cocktail for 48 h (Step 3).
The application of RNA derived from an established and
well characterized RCC cell line comprises the generic
component of this approach. Total RNA is isolated from
this cell line, providing a virtually unlimited source of
TAAs. This bypasses the need for RNA preparation from,
often limited, individual patient tumor tissues. Fully
matured DCs, loaded with generic RNA can than be
applied for vaccination of mRCC patients (Step 4).
The autologous LCLs are instrumental for analysing the
activation, expansion and perseverance of specific T cell
responses after vaccination. Transfection of autologous
LCLs with RCC-derived RNA (Step 5) will generate APCs
expressing different pMHC complexes with various TAA
epitopes. By co-cultivating these APCs with autologous
post-treatment PBMCs, under limiting dilution culture
conditions, it should be possible to track the development
of both MHC class I and class II-restricted T cells contrib-
uting to antitumor immunity (Step 6). Either RCC-26-
derived RNA or single-species RNAs corresponding to
individual TAAs expressed by RCC-26 cells [23] can be
employed to potentially identify the fine specificity of
emerging T cell responses.
Immature DCs can be efficiently transfected with in vitro 
transcribed mRNA using lipofection
Steps 1 and 2 of the strategy described above are standard
procedures nowadays. In our studies, the generation of
monocyte-derived iDCs in the presence of GM-CSF and
IL-4 yielded considerable cell numbers (approximately
50% of the isolated monocytes) and subsequent activa-
tion of the iDCs could be achieved by stimulation with a
pro-inflammatory cytokine cocktail (TNF-α, IL-1β, PGE2
and IL-6) for 48 h [26]. This activation resulted in fully
mature DCs (mDCs) showing high expression of matura-
tion and activation markers, like CD86, CD80, CD83,
CD40 and the chemokine receptor CCR7. In contrast, the
monocyte marker CD14 was completely down-regulated
(Fig. 2).
Different techniques are discussed in the literature for
loading DCs with RNA (Step 3) [30-36] but the optimal
procedure for generating fully immunocompetent RNA-
expressing DCs for in vivo application still has to be
defined. In our studies, we utilized the method of lipofec-
tion to load DCs with tumor-derived RNA. To quantify the
efficiency of RNA transfection, iDCs were lipofected with
in vitro-transcribed EGFP mRNA using the transfectionJournal of Translational Medicine 2005, 3:29 http://www.translational-medicine.com/content/3/1/29
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reagent DMRIE-C at day 7 of culture. DMRIE-C was cho-
sen since it showed the lowest toxicity and highest trans-
fection efficiency compared to other transfection reagents,
such as DOTAP and TransFast (data not shown). Flow
cytometric analysis of EGFP expression 48 h post-transfec-
tion revealed an average transfection rate of 20 – 40%,
depending on the conditions chosen (Fig. 3).
In addressing the question whether subsequent matura-
tion of transfected DCs had an impact on protein expres-
sion, we found an increase in EGFP-positive cells when
transfected DCs (2.5 µg mRNA/0.5 × 106  cells) were
exposed to the maturation cocktail for 48 h (Fig. 3A). The
lipofection efficiency could also be enhanced by applica-
tion of increasing amounts of EGFP mRNA. For example,
the use of 5.0 µg mRNA/0.5 × 106 cells increased the per-
centage of positive cells by 10% compared to 2.5 µg
mRNA (Fig. 3B). In all cases, lipofection of mRNA
resulted in a broad range of protein density, generating
DCs with EGFP protein expression ranging from low to
very high levels (Fig. 3A, B and 3C).
Lipofection of DCs with RNA does not adversely interfere 
with cell maturation
Since we were interested to know whether RNA lipofec-
tion of iDCs interfered with DC maturation, we co-incu-
bated the transfected iDCs with the different lipofection
components (lipid + RNA), with or without maturation
cytokine cocktail, and analyzed the DC phenotype by flow
cytometry 48 h later. Incubation of iDCs with lipid plus
RNA had no significant impact on DC maturation (Fig. 4,
two left panels). A fully mature DC phenotype could only
be induced by incubation with the pro-inflammatory
cytokine cocktail, resulting in high expression of CD40
and up-regulation of CD86 and CD83 expression. Also,
expression of the chemokine receptor CCR7, which is cru-
cial for the migration of DCs to secondary lymphoid
Strategy for a generic RNA-pulsed DC vaccine for metastatic renal cell carcinoma Figure 1
Strategy for a generic RNA-pulsed DC vaccine for metastatic renal cell carcinoma. See text for detailed explanation.
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organs [37-40], was significantly up-regulated only after
cytokine-induced maturation of the DCs (Fig. 4, two right
panels).
Additionally, we analyzed the cytokines secreted by the
DCs in order to determine whether loading of iDCs with
RNA altered their cytokine production capacity. We tested
supernatants of differentially treated DCs using a cytokine
multiplex panel. On day 7 of culture, iDCs were incubated
with the different components (lipid alone, RNA alone or
RNA in combination with lipid). Subsequently, DCs were
either matured or kept in the immature stage for 48 h
before supernatants were harvested and analyzed. IL-
12p70 was detected at low levels while IL-10 and IL-2
were detected in slightly higher amounts, but neither the
applied RNA nor the lipofection reagent showed any sig-
nificant impact on the levels of cytokines secreted by iDCs
or mDCs. In general, maturation of DCs led to an
increased secretion of these three cytokines (data not
shown).
Specific effector-memory CTLs can be activated by DCs 
lipofected with tumor cell line-derived RNA
DCs applied for vaccination (Fig. 1, Step 4) must be com-
petent to stimulate specific immune responses. To evalu-
ate the specific immunostimulatory potential of RNA-
loaded DCs for effector-memory CTLs, iDCs derived from
HLA-A*0201-positive healthy donors were transfected on
day 7 with total RNA prepared from the tumor line RCC-
26 using lipofection (5.0 µg RNA/0.5 × 106  DCs).
Phenotype of mature DCs Figure 2
Phenotype of mature DCs. The incubation of monocyte-derived iDCs with a pro-inflammatory cytokine cocktail composed 
of IL-1β, IL-6, TNF-α and PGE2 for 48 h induced a fully mature DC phenotype. Status of maturation was measured by staining 
of different DC maturation and activation markers followed by flow cytometric analysis.
HLA-DR CD86 CD80 CD83
DC-SIGN CD40 CCR7 CD14
Mean Fluoresence IntensityJournal of Translational Medicine 2005, 3:29 http://www.translational-medicine.com/content/3/1/29
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Following transfection, DCs were matured for 48 h. On
day 9, transfected DCs were co-cultivated with TIL-26
cells. TIL-26 line is a tumor antigen-specific CTL line that
was expanded from the tumor-infiltrating lymphocyte
population of patient-26 and was demonstrated to recog-
nize a RCC-26-associated determinant presented by HLA-
A*0201-encoded molecules [14]. The TIL-26-derived
clone, TIL-26(GG) [41] was employed for all experiments.
Transfection of immature DCs with EGFP mRNA Figure 3
Transfection of immature DCs with EGFP mRNA. iDCs were transfected by lipofection using DMRIE-C and in vitro-tran-
scribed EGFP mRNA. A) 2.5 µg EGFP mRNA/0.5 × 106 iDCs were transfected and the DCs were kept either as immature cells 
or matured using a cytokine cocktail. B) 2.5 µg and 5.0 µg EGFP mRNA/0.5 × 106 iDCs, respectively, were transfected and the 
DCs matured. EGFP expression was analyzed by flow cytometry 48 h after transfection (grey histograms). DCs transfected 
with H2O only were used as a control (broken line). C) EGFP-expression in transfected DCs was visualized using a fluorescent 
microscope.
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After a 24 h incubation period, the supernatants of TIL-
26(GG) co-cultured with DCs were harvested and
assessed for IFNγ in a standard ELISA assay.
To demonstrate specificity, the TIL-26(GG) clone was co-
cultivated with different cell lines. Only co-culture with
RCC-26 cells, but not with autologous LCL-26, the nor-
mal kidney cell line (NKC-26), or the HLA-A*0201-
matched tumor cell line RCC-53 induced IFNγ-release,
indicating that only RCC-26 cells provided the specific lig-
and for TIL-26 activation (Figure 5A). Furthermore, TIL-
26(GG) had no LAK or NK activitiy directed against Daudi
or K562 cells. DCs transfected with the RCC-26-derived
RNA, but not DCs alone, were able to induce IFNγ-secre-
tion in TIL-26(GG) cells, indicating that the RCC-26-
derived RNA was also capable of providing the TIL-26-
specific epitope to the DCs. DCs transfected with RNA
derived from RCC-53 or LCL-26, both of which are HLA-
A2-positive cell lines that do not express the TIL-26
epitope (Fig. 5A), were not recognized by the T cell clone,
further confirming the specificity of the T cell activation
by RNA-pulsed DCs (Fig. 5B and 5C). RNA-loaded DCs
prepared from HLA-A*0201-negative donors were also
unable to specifically reactivate TIL-26 cells (data not
shown).
Among individual experiments, responses stimulated by
DCs reached levels ranging from 20% – 80% of those seen
with stimulation by the RCC-26 cell line. These variations
in the stimulation capacity of the RNA-loaded DCs might
possibly be a consequence of variations in the donor DCs
that were not readily apparent from characterization of
the DC phenotype. Alternatively, differences in the preva-
lence of epitope-specific RNA in various RNA
Lipofection of DCs with RNA does not adversely affect their phenotype Figure 4
Lipofection of DCs with RNA does not adversely affect their phenotype. iDCs were incubated with DMRIE-C plus RNA, 
as described in the Methods section. After a 4 h incubation, the DCs were either kept immature or matured using a cytokine-
cocktail. The DC phenotype was analyzed by flow cytometry 48 h after transfection.
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preparations or differences in transfection efficiencies
may have contributed to these variations. In the optimal
case, the TIL-26 activation capacity of RCC-26-transfected
DCs was nearly as high as the stimulating potential of the
RCC-26 cell line itself (Fig. 5B). Figure 5C shows another
experiment in which RNA-loaded DC stimulation was
only about 30% of the level of RCC-26 cells. These data
are included in Figure 5D, providing pooled results of four
independent experiments.
Induction of RCC-26-specific CTL-lines using RNA-pulsed 
DCs
To analyze the capacity of RNA-pulsed DCs for de novo
priming of antigen-specific T cell responses, we generated
DCs from HLA-A*0201-positive healthy donors and used
them as APCs after lipofection with total RNA derived
from either the RCC-26 or RCC-53 cell lines (5.0 µg RNA/
0.5 × 106 DCs). Autologous PBMCs were cocultivated with
the transfected mDCs in a ratio of 8:1 during the first
round of stimulation and in a ratio of 4:1 thereafter. We
found that DCs transfected with either RCC-26- or RCC-
53-derived RNA functioned as potent APCs and were able
to induce RCC-26- and RCC-53-associated T cell
Reconstitution of the TIL-26 epitope in HLA-A*0201-positive DCs after lipofection with RCC-26-derived total RNA Figure 5
Reconstitution of the TIL-26 epitope in HLA-A*0201-positive DCs after lipofection with RCC-26-derived total RNA. 
A) To demonstrate the specificity of TIL-26(GG) for an epitope provided by RCC-26, different tumor cell lines were co-culti-
vated with the T cell clone in a ratio of 5:1 and supernatants were analyzed 24 h later. B, C and D) HLA-A*0201-positive 
iDCs were transfected using DMRIE-C with total RNA derived from RCC tumor cell lines. 48 h after transfection and matura-
tion the mDCs were co-cultivated with the TIL-26(GG) T cell clone at a ratio of 5:1 for 24 h. B and C show two individual 
experiments contributing to the diagram in D, showing pooled data for four independent experiments. All experiments were 
carried out in triplicates and activation of T cells was measured by analysis of IFNγ secretion.
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responses, respectively, after three (in the case of RCC-26)
or four (in the case of RCC53) rounds of weekly restimu-
lation (Fig. 6).
The CTL line induced with RCC-26 RNA-transfected DCs
was analyzed using a 4-h 51Cr-release assay. They showed
an efficient specific lysis of the RCC-26 cell line itself but
Induction of RCC-specific CTLs using RNA-transfected DCs as APCs Figure 6
Induction of RCC-specific CTLs using RNA-transfected DCs as APCs. Monocyte-derived DCs were transfected with total 
RNA (5 µg/0.5 × 106 DCs) isolated either from RCC-26 (A) or RCC-53 (B) tumor cell lines. After a maturation period of 48 h 
the DCs were co-cultivated with autologous PBMCs (PBMC/DC ratio = 8:1) for 10–12 days following three rounds of restim-
ulation (PBMC/DC ratio = 4:1). In the case of RCC-53 specific CTLs (B) an additional round of restimulation was carried out 
using autologous LCLs transfected with RCC-53-derived total RNA. The PBMC/DC co-culture was supplemented with IL-7 
and IL-2 as described in the Methods section. A) RCC-26-specific CTLs were harvested three days after the last round of res-
timulation and specific lysis was analyzed in a standard 4-h 51Cr-release assay. B) RCC-53-specific T cells were harvested 10 
days after the last round of restimulation and specificity of the T cells was determined by measuring IFNγ in the 24 h superna-
tant media T cell/target cell co-cultures (1.5 × 104 T cells : 1.5 × 104 target cells per 200 µl).
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not of autologous unloaded LCL-26 cells (Fig. 6A).
Likewise, the T cell line primed with RCC-53-loaded RNA
was activated specifically to secrete IFNγ using either RCC-
53 tumor cells or autologous LCLs pulsed with RCC-53-
derived total RNA (Fig. 6B). Re-activation of specific T
cells by RNA-transfected autologous LCLs thereby can be
instrumental for analyzing specific T cell responses devel-
oping as a consequence of DC vaccination (Fig. 1, Step 6).
In fact, it was possible to maintain the RCC-53-specific T
cell line with autologous LCLs transfected with RCC-53-
derived RNA. These observations indicate that continuous
preparation of DCs from patient PBMCs either for analy-
sis of T cell responses or to maintain T cell lines ex vivo
may not be required.
In both examples, Daudi and/or K562 cells were used to
measure non-MHCrestricted lysis or cytokine secretion,
respectively. A low level of activity was detected in the
uncloned T cell populations but this was decidedly lower
than the specific reactivation achieved using the corre-
sponding tumor cell lines.
Discussion
In this report we present our strategy for the development
of a generic RNA-pulsed DC vaccine for mRCC. Patients
with mRCC have a poor prognosis and few treatment
options; therefore, most clinical trials analyzing the effi-
cacy of cell-based vaccines have studied the treatment of
patients with advanced disease. A DC-based vaccine pre-
senting RCC-associated antigens comprises a promising
approach for generating antitumor responses, since DCs
are the most potent antigen-presenting cells and they are
capable of de novo priming of antigen-specific CD4 and
CD8 effector cells from naïve T cells in vivo [reviewed in
[42,43]]. Myeloid DCs can be generated from monocytes
when cultured in the presence of GM-CSF and IL-4 ex vivo
and thereby they are easily accessible in considerable
numbers [44].
In contrast to melanoma where different peptide-specific
vaccination approaches have been studied in numerous
clinical trials, less is known about TAAs in RCC. Therefore,
most clinical trials initiated to evaluate the safety and fea-
sibility of DC-based vaccines for RCC so far have utilized
DCs that were loaded with autologous tumor lysates
[17,18,45-47]. This approach has the disadvantage that
patient material must be available and often may be lim-
ited. As an alternative, two clinical trials have utilized
tumor lysates prepared from established allogeneic RCC
lines, which overcomes this handicap by providing a
generic source of tumor cells for preparation of tumor
lysates [18,48]. However, it is unclear how efficiently
various TAAs are transferred by cell lysates. An attractive
alternative is to utilize DCs transfected with defined or
total tumor-derived RNA. By applying RNA, transfer of
TAAs can be quantified using surrogate marker RNA spe-
cies expressed by the tumor cell lines, which is not possi-
ble when cell lysates are used [36].
A recent phase I clinical trial with mRCC patients who
received immunizations with DCs expressing autologous
tumor-derived RNA demonstrated the feasibility and lack
of toxicity of such vaccinations [19]. In this study, the
authors employed iDCs that were incubated with naked
RNA on the day of administration, relying on the natural
capacity of DCs to take up RNA. Based on the finding that
iDCs may induce tolerance [49,50], the use of mDCs
would now seem to be a better strategy.
Several different methods for achieving RNA delivery to
DCs have been analyzed to date, whereby electroporation
and lipofection of DCs have been investigated most inten-
sively [19,28,30-36]. The type of delivery that yields DCs
capable of eliciting optimal T cell responses in vivo has yet
to be determined. Our own studies revealed that electro-
poration yielded higher percentages DCs expressing pro-
tein, however, the levels of protein expression on a per cell
basis were higher in lipofected DCs [36]. How these dif-
ferences impact on de novo priming of T cells remains to
be determined.
Here, we utilized DCs transfected with RCC-26-derived
total RNA using the technique of lipofection. We selected
the cationic lipid reagent DMRIE-C, since it provided the
most efficient transfer of RNA and showed the lowest DC
toxicity. We achieved a transfection rate of up to 40%
when iDCs were transfected with EGFP mRNA and subse-
quently matured using a cytokine cocktail. It has been
reported recently that comparatively high transfection
efficiencies could also be obtained with other transfection
reagents [34]. Here, the authors demonstrated an average
transfection efficiency of 47%, with a viability of 92%,
when mature DCs were transfected with an in vitro-tran-
scribed EGFP RNA.
Some studies revealed that transfection with mRNA could
partially activate DCs, presumably due to double-
stranded secondary structures of the mRNA and toll-like
receptor signalling [51-53]. Therefore, we were interested
in the question whether the components used during our
procedure of lipofection would influence the maturation
status of the DCs. We found no evidence that application
of lipid and RNA, at the concentrations used in our
experiments, led to significant DC activation. Thereby,
incubation with a defined pro-inflammatory cytokine
cocktail was still necessary to induce a distinct mature DC
phenotype. Furthermore, transfection of DCs with mRNA
had no significant influence on the cytokines produced by
the DCs. Thus, neither DC phenotype nor cytokine secre-Journal of Translational Medicine 2005, 3:29 http://www.translational-medicine.com/content/3/1/29
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tion levels were modulated by the lipofection compo-
nents and/or procedure.
To achieve effective T cell responses in patients, DCs gen-
erated ex vivo should be competent both in re-activating
pre-existing effector-memory CTLs and in priming specific
T cells de novo. Antitumor CTL responses can often be
detected in RCC patients [3-7,41]. However, these T cell
responses are insufficient in disease control, possibly due
to a late developing general immune suppression or due
to the encounter of such T cells with defective antigen-pre-
senting cells [54-60]. Stimulation of memory T cells with
antigen-loaded DCs generated ex vivo may overcome these
limitations and enhance tumor-specific T cell immunity
in RCC patients.
To test whether DCs lipofected with RCC-derived RNA
could reactivate specific CTLs, we used the tumor-specific
T cell clone, TIL-26(GG), which is HLA-A2- restricted and
specific for a TAA expressed by RCC-26 cells [14,41]. We
could show that DCs lipofected with RCC-26-derived
RNA were highly competent in reactivating these TIL-26
cells. In contrast, DCs transfected with RNA derived from
RCC-53, a cell line which does not express this particular
TIL-26 epitope, were unable to activate TIL-26(GG) cells,
demonstrating the specificity of this response. We found
that RNA-transfected DCs varied in their capacity to
restimulate TIL-26 cells, often being weaker than RCC-26
tumor cells. We have shown elsewhere [36] that trans-
ferred RNA has a very short half-life in DCs so that pep-
tides for MHC presentation will presumably only be
available from one round of protein synthesis. Variations
in ligand reconstitution on DCs thereby will be depend-
ent upon the amount of RNA transferred to the DCs
whereas tumor cells can generate new transcripts that can
provide a continuous supply of peptides for MHC
presentation.
A second important functional characteristic of RNA-
pulsed DCs, namely their capacity to prime specific T cells
de novo, was also demonstrated in our studies. We found
that DCs lipofected with RCC-26- or RCC-53-derived
RNAs were capable of inducing specific T cell responses
against the corresponding tumor cell lines. Phenotype
analysis of de novo primed T cell populations revealed that
they contained both CD4+  and CD8+  T cells. Greater
expansion of CD8+ T cells occurred during restimulation,
ultimately yielding altered CD4+/CD8+  ratios when
compared to naïve lymphocyte populations of healthy
donors (data not shown).
Although, the in vitro-primed T cell lines showed some
non-MHC-restricted activity directed against NK-sensitive
K562 or LAK-sensitive Daudi cells, substantially stronger
responses were detected against the specific tumor cell
lines whose RNA was used for priming. In other studies,
we demonstrated that non-MHC-restricted T cells and NK
cells may play a significant role in anti-RCC immunity
[61,62]. Therefore, we consider the induction of these
innate effector cells by the DCs to be an advantage.
One critical aspect in generating and characterizing spe-
cific T cells is the need for high numbers of DCs for use as
potent APCs. During the generation of the RCC-53-spe-
cific T cell line, autologous LCLs transfected with RCC-
derived RNA could be successfully substituted as APCs for
restimulation, in addition to being used for function and
specificity studies. This demonstrated that RNA-trans-
fected LCLs could efficiently provide pMHC ligands of
interest and thereby provided an easily accessible alterna-
tive to RNA-loaded DCs. However, it must be cautioned
that LCLs could replace DCs only after specific T cell
responses had developed in order to avoid reactivation of
EBV-specific T cells. Cultures can be established under
limiting dilutions conditions in order to separate T cells
with different specificities. Alternatively, the use of mini-
EBV constructs that encode a limited number of EBV pro-
teins, yet still retain the capacity to immortalize B cells,
provides an elegant means to reduce this handicap [63].
A more decisive point in analyzing responses to a generic
vaccine based on total tumor RNA is that autologous LCLs
can provide a helpful tool for elucidating the fine specifi-
city of T cell responses. Following loading with RNA, they
can present epitopes in both class I and class II molecules.
Furthermore, LCLs can be transfected with any TAA
mRNA of interest in order to assess the emergence of TAA-
specific T cells following vaccination. Previous clinical tri-
als have indicated that following DC vaccination T cell
responses could be detected against oncofetal antigen
[18,19], human telomerase reverse transcriptase (hTERT)
[19] and G250/CA-IX antigens [19]. Transfection of LCLs
with mRNA encoding these specific TAAs could be useful
for evaluating specific T cell responses.
Two GMP-certified, genetically engineered RCC-26 cell
lines, RCC-26/B7.1/IL-2 and RCC-26/B7.1/IL-7, are cur-
rently studied in phase I clinical trials [13,23]. These
tumor cell lines could easily serve as sources of GMP-qual-
ity RNA for further development of the proposed generic
DC-based vaccine approach. Findings concerning feasibil-
ity, toxicity and potential induction of autoimmunity
emerging from these ongoing phase I trials will also be
useful for designing a clinical trial based on RNA-loaded
DCs. RNA generated from these GMP-certified RCC-26
cell lines will encode an array of TAAs present in the
tumor cells. For example, both vaccine variants have been
demonstrated to show over-expression of PRAME, oncofe-
tal antigen, adipophilin and hTERT RNAs [23], all of
which have been often found to be over-expressed in freshJournal of Translational Medicine 2005, 3:29 http://www.translational-medicine.com/content/3/1/29
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tumors and to serve as targets for T cell responses [11,18-
21,64,65]. The immune monitoring tools specific for such
molecules that prove useful for defining T cell responses
that develop following tumor cell vaccination also can be
used for analyzing specific T cell responses to the generic
DC-based vaccine proposed here. As more information
emerges regarding specific TAAs that can be used to target
immune responses to RCC, it will be possible to develop
defined vaccines based on the use of pools of RNA encod-
ing selected TAAs. Such an approach has recently been
described for melanoma [35].
Conclusion
We describe a DC-based vaccine strategy for RCC patients
using a generic source of RNA derived from a well charac-
terized tumor cell line. When DCs derived from HLA-A2-
positive donors were loaded with tumor cell line-derived
RNA using the method of lipofection, they were able to re-
activate effector-memory CTLs and were also capable of
priming T cells de novo to mediate cytotoxicity or secrete
cytokine after contact with RCC cells. The availability of
GMP-certified cells, expressing a variety of TAAs that are
shared by many RCC and can provide target epitopes for
T cells will allow this strategy to be more easily adapted for
clinical testing. Furthermore, the ability to load tumor cell
line-derived RNA into autologous LCLs provides a useful
tool for immune monitoring.
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